Neutralizing IgG antibody seroprevalence, efficacy and safety post covishield vaccination
A follow up study
Keywords:
COVID-19, vaccine, covishield, neutralizing IgG antibodies titres, efficacy, safetyAbstract
COVID-19, a pandemic caused by severe acute respiratory syndrome (SARS) corona virus-2 has been a worldwide challenge for the entire mankind. However, a safe and efficacious vaccine would be clinically valuable to reduce the risks of COVID-19. In this study, we aimed to assess the seroprevalence of the Neutralizing IgG Antibodies six months after completion of both the doses of Covishield Vaccination (ChAdox1 nCoV-19) and compare it with the IgG titres one month after the first dose and one month after the second dose of the vaccine respectively. The efficacy, safety and comorbidities related to the vaccine were also assessed at different time intervals. The levels of IgG antibodies were estimated in 72 subjects from the Teerthanker Mahaveer Medical College & Research Centre (who turned up after six months of the complete regimen of Covishield Vaccination) using the Enzyme-Linked Immunosorbent Assay (ELISA) Technique. A highly significant increase (p= 0.00) in the neutralizing Antibodies titre was seen in fully vaccinated individuals post six months when compared to the titres of post one month of 1st & 2nddoses. It can therefore be concluded that (ChAdox1 nCoV-19) Covishield Vaccination if administered in full regimen has both acceptable efficacies as well as safety profile.
Downloads
References
Ouassou H, Kharchoufa L, Bouhrim M, Daoudi N, Imtara H, Bencheikh N et al. The Pathogenesis of Coronavirus Disease 2019 (COVID-19): Evaluation and Prevention. Journal of Immunology Research,2020;1-7.
Chen Y, Guo Y, Pan Y, Zhao Z. Structure analysis of the receptor binding of 2019-nCoV. Biochemical and Biophysical Research Communications. 2020;525(1):135-140.
Walls A, Park Y, Tortorici M, Wall A, McGuire A, Veesler D. Structure, Function, and Antigenicity of the SARS-CsoV-2 Spike Glycoprotein. Cell. 2020;181(2):281-292.e6.
https://www.who.int/emergencies/diseases/novel-coronavirus-2019/covid-19-vaccines/advice[accessed at 28 Jan 2022]
The draft landscape of covid-19 candidate vaccines, 2020. Available from: https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1.[Accessed at 3 Feb 2022]
Ramasamy M, Minassian A, Ewer K, Flaxman A, Folegatti P, Owens D et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. The Lancet. 2020;396(10267):1979-1993.
Barrett J, Belij-Rammerstorfer S, Dold C, Ewer K, Folegatti P, Gilbride C et al. Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional Antibodies responses. Nature Medicine. 2020;27(2):279-288.
Efficacy-of-covid-vaccines;Newindianexpress,2021.Available from:https://www.newindianexpress.com/nation/2021/nov/19/efficacy-of-covid-vaccines-satisfactory-finds-icmr-study-as-over-115-crore-inoculated-in-india-so-far-2385444.html[Accessed at 2 Feb 2022]
COVID-19 Vaccines Advice Who. int, 2022. Available from: COVID-19 IgG [package insert]. Milano: DIA.PRO Diagnostic Bioprobes S.r.l.;2020.
Cascella M, Rajnik M, Aleem A, Dulebohn SC, & Di Napoli R. Features, Evaluation, and Treatment of Coronavirus (COVID-19). In StatPearls. StatPearls Publishing, 2022
Anti-SARS-CoV-2 Monoclonal Antibodies, 2022. Available at: https://www.idsociety.org/covid-19-real-time-learning-network/therapeutics-and-interventions/monoclonal-antibodies/. [Accessed at 25 Jan 2022].
Statement for healthcare professionals: How COVID-19 vaccines are regulated for safety and effectiveness Who. int, 2022. Available from: https://www.who.int/news/item/11-06-2021-statement-for-healthcare-professionals-how-covid-19-vaccines-are-regulated-for-safety-and-effectiveness.[Accessed at 2 Feb 2022]
Coronavirus Disease (COVID-19) WHO - Prequalification of Medical Products (IVDs, Medicines,
Vaccines and Immunization Devices, Vector Control), 2022. Available from: https://extranet.who.int/pqweb/vaccines/covid-19-vaccines.[Accessed at 2 Feb 2022]
Gobbi F, Buonfrate D, Moro L, Rodari P, Piubelli C, Caldrer S et al. Antibodies Response to the BNT162b2 mRNA COVID-19 Vaccine in Subjects with Prior SARS-CoV-2 Infection. Viruses. 2021;13(3):422.
Kadkhoda K. COVID ‐19: are neutralizing antibodies neutralizing enough? Transfusion. 2020;60(7):1602-1603.
Pulendran B, Ahmed R. Immunological mechanisms of vaccination. Nature Immunology. 2011;12(6):509-517.
C.K. Jayaram Paniker, R. Ananthnarayan. 2020. Paniker’s Textbook of Microbiology. [S.l.]: Orient Blackswan Pvt. Ltd.
Rawat K, Kumari P, Saha L. COVID-19 vaccine: A recent update in pipeline vaccines, their design and development strategies. European Journal of Pharmacology. 2021; 892:173751.
After COVID Infection, Antibodies Highly Protective for Months, Medscape, 2022. Available at: https://www.medscape.com/viewarticle/943154.[Accessed at 29 Jan 2022]
Centres for Disease Control and Prevention. Centres for Disease Control and Prevention, 2019. Available from: https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html [Accessed at 4 Feb 2022]
Suryasa, I. W., Rodríguez-Gámez, M., & Koldoris, T. (2021). Get vaccinated when it is your turn and follow the local guidelines. International Journal of Health Sciences, 5(3), x-xv. https://doi.org/10.53730/ijhs.v5n3.2938
Suryasa, I. W., Rodríguez-Gámez, M., & Koldoris, T. (2021). Health and treatment of diabetes mellitus. International Journal of Health Sciences, 5(1), i-v. https://doi.org/10.53730/ijhs.v5n1.2864
Khidoyatova, M. R., Kayumov, U. K., Inoyatova, F. K., Fozilov, K. G., Khamidullaeva, G. A., & Eshpulatov, A. S. (2022). Clinical status of patients with coronary artery disease post COVID-19. International Journal of Health & Medical Sciences, 5(1), 137-144. https://doi.org/10.21744/ijhms.v5n1.1858
Published
How to Cite
Issue
Section
Copyright (c) 2022 International journal of health sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles published in the International Journal of Health Sciences (IJHS) are available under Creative Commons Attribution Non-Commercial No Derivatives Licence (CC BY-NC-ND 4.0). Authors retain copyright in their work and grant IJHS right of first publication under CC BY-NC-ND 4.0. Users have the right to read, download, copy, distribute, print, search, or link to the full texts of articles in this journal, and to use them for any other lawful purpose.
Articles published in IJHS can be copied, communicated and shared in their published form for non-commercial purposes provided full attribution is given to the author and the journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
This copyright notice applies to articles published in IJHS volumes 4 onwards. Please read about the copyright notices for previous volumes under Journal History.
